Differential Regulation of Interleukin-10 (IL-10) and IL-12 by Glucocorticoids In Vitro
-
- Jeroen Visser
- From the Division of Immunological and Infectious Diseases, TNO Prevention and Health, Leiden; and the Division of Medical Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands.
-
- Anette van Boxel-Dezaire
- From the Division of Immunological and Infectious Diseases, TNO Prevention and Health, Leiden; and the Division of Medical Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands.
-
- Dion Methorst
- From the Division of Immunological and Infectious Diseases, TNO Prevention and Health, Leiden; and the Division of Medical Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands.
-
- Tibor Brunt
- From the Division of Immunological and Infectious Diseases, TNO Prevention and Health, Leiden; and the Division of Medical Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands.
-
- E. Ronald de Kloet
- From the Division of Immunological and Infectious Diseases, TNO Prevention and Health, Leiden; and the Division of Medical Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands.
-
- Lex Nagelkerken
- From the Division of Immunological and Infectious Diseases, TNO Prevention and Health, Leiden; and the Division of Medical Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden, The Netherlands.
書誌事項
- 公開日
- 1998-06-01
- DOI
-
- 10.1182/blood.v91.11.4255
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Antigen-presenting cells are thought to modulate the development of Th1 and Th2 cells by the secretion of interleukin-10 (IL-10) and IL-12. Because glucocorticoids (GC) favor the development of Th2 responses, we determined whether dexamethasone (DEX) and hydrocortisone (HC) have differential effects on lipopolysaccharide-induced IL-10 and IL-12 production in whole-blood cultures. Significant inhibition of IL-12(p40) and IL-12(p70) was found with 10−8 mol/L and 10−9 mol/L DEX respectively, whereas IL-10 was relatively insensitive or even stimulated. Accordingly, the expression of IL-12(p40) and IL-12(p35) mRNA was more sensitive to DEX than IL-10 mRNA. The glucocorticoid receptor (GR) antagonist RU486 enhanced IL-12 production and largely abrogated the inhibition of IL-12 by GC, indicating that this suppression was mainly GR-mediated. High concentrations of RU486 were inhibitory for IL-10, suggesting that GC may exert a positive effect on IL-10. In the presence of neutralizing anti–IL-10 antibodies, DEX was still capable of IL-12 suppression whereas RU486 still enhanced IL-12 production, indicating that GC do not modulate IL-12 via IL-10 exclusively. Taken together these results indicate that GC may favor Th2 development by differential regulation of IL-10 and IL-12.</jats:p>
収録刊行物
-
- Blood
-
Blood 91 (11), 4255-4264, 1998-06-01
American Society of Hematology
